FAKTORI RIZIKA ZA NASTANAK SIMPTOMATSKE EPILEPSIJE KOD PACIJENATA NAKON MOŽDANOG UDARA

  • Biljana Živadinović
  • Aleksandra Lučić –Prokin3
  • , Jelena Živadinović
  • Aleksandar Stojanov
Ključne reči: rizik faktori, epilepsija, moždani udar

Sažetak


Moždani udar (MU) jedan je od vodećih uzroka smrtnosti u starijoj populaciji. Oko 50% obolelih od moždanog udara ima neki vid slabosti i posledica. Simptomatska epilepsija (post stroke epilepsy – PSE; eng.) jedna je od njih.

Cilj rada bio je da utvrdi učestalost PSE u ispitivanoj grupi pacijenata nakon MU, razliku u učestalosti PSE u grupi sa hemoragijskim i ishemijskim MU, uticaj veličine i lokalizacije lezije, kao i uticaj postojanja komorbiditeta za nastanak PSE.

U pitanju je bila prospektivna studija, koja je analizirala bolesnike sa prvim MU (ishemijske i hemoragijske geneze) sa periodom praćenja od dve godine.

Od ukupno 536 lečenih bolesnika bilo je analizirano njih 267 (starosti 47 godina do 92 godine), koji su imali prvi MU. U kontrolnoj grupi (n = 246) nije došlo do pojave PSE, dok je njih 21 razvilo PSE u periodu od dve godine nakon MU. Kortikalne i subkortikalne lezije, kao i mlađa životno doba, pokazali su statističku značajnost za pojavu PSE (p < 0,05). Nismo dokazali statističku značajnost za nastanak PSE kada je u pitanju veličina lezija i vrsta MU. Udruženo postojanje kardiološkog i plućnog oboljenja statistički je češće bilo povezano sa nastankom PSE nakon MU (p < 0,05).

Učestalost PSE u našoj grupi ispitanika bila je 7,86%. Mlađe životno doba, kao i lokalizacija lezije pokazali su statističku značajnost za nastanak PSE, dok veličina lezije i vrsta MU to nisu pokazali u našoj grupi ispitanika. Od značaja za nastanak PSE pokazalo se i postojanje udruženog pulmonalnog i kardiološkog oboljenja.

Reference

800x600

Normal

0

false

false

false

EN-US

X-NONE

X-NONE

DefSemiHidden="false" DefQFormat="false" DefPriority="99"

LatentStyleCount="371">

UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>

UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>

UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>

UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>

UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>

UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>

UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>

UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>

Name="index 1"/>

Name="index 2"/>

Name="index 3"/>

Name="index 4"/>

Name="index 5"/>

Name="index 6"/>

Name="index 7"/>

Name="index 8"/>

Name="index 9"/>

UnhideWhenUsed="true" Name="toc 1"/>

UnhideWhenUsed="true" Name="toc 2"/>

UnhideWhenUsed="true" Name="toc 3"/>

UnhideWhenUsed="true" Name="toc 4"/>

UnhideWhenUsed="true" Name="toc 5"/>

UnhideWhenUsed="true" Name="toc 6"/>

UnhideWhenUsed="true" Name="toc 7"/>

UnhideWhenUsed="true" Name="toc 8"/>

UnhideWhenUsed="true" Name="toc 9"/>

Name="Normal Indent"/>

Name="footnote text"/>

Name="annotation text"/>

Name="header"/>

Name="footer"/>

Name="index heading"/>

UnhideWhenUsed="true" QFormat="true" Name="caption"/>

Name="table of figures"/>

Name="envelope address"/>

Name="envelope return"/>

Name="footnote reference"/>

Name="annotation reference"/>

Name="line number"/>

Name="page number"/>

Name="endnote reference"/>

Name="endnote text"/>

Name="table of authorities"/>

Name="macro"/>

Name="toa heading"/>

Name="List"/>

Name="List Bullet"/>

Name="List Number"/>

Name="List 2"/>

Name="List 3"/>

Name="List 4"/>

Name="List 5"/>

Name="List Bullet 2"/>

Name="List Bullet 3"/>

Name="List Bullet 4"/>

Name="List Bullet 5"/>

Name="List Number 2"/>

Name="List Number 3"/>

Name="List Number 4"/>

Name="List Number 5"/>

Name="Closing"/>

Name="Signature"/>

UnhideWhenUsed="true" Name="Default Paragraph Font"/>

UnhideWhenUsed="true" Name="Body Text"/>

Name="Body Text Indent"/>

Name="List Continue"/>

Name="List Continue 2"/>

Name="List Continue 3"/>

Name="List Continue 4"/>

Name="List Continue 5"/>

Name="Message Header"/>

Name="Salutation"/>

Name="Date"/>

Name="Body Text First Indent"/>

Name="Body Text First Indent 2"/>

Name="Note Heading"/>

Name="Body Text 2"/>

Name="Body Text 3"/>

Name="Body Text Indent 2"/>

Name="Body Text Indent 3"/>

Name="Block Text"/>

Name="Hyperlink"/>

Name="FollowedHyperlink"/>

Name="Document Map"/>

Name="Plain Text"/>

Name="E-mail Signature"/>

Name="HTML Top of Form"/>

Name="HTML Bottom of Form"/>

Name="Normal (Web)"/>

Name="HTML Acronym"/>

Name="HTML Address"/>

Name="HTML Cite"/>

Name="HTML Code"/>

Name="HTML Definition"/>

Name="HTML Keyboard"/>

Name="HTML Preformatted"/>

Name="HTML Sample"/>

Name="HTML Typewriter"/>

Name="HTML Variable"/>

Name="Normal Table"/>

Name="annotation subject"/>

Name="No List"/>

Name="Outline List 1"/>

Name="Outline List 2"/>

Name="Outline List 3"/>

Name="Table Simple 1"/>

Name="Table Simple 2"/>

Name="Table Simple 3"/>

Name="Table Classic 1"/>

Name="Table Classic 2"/>

Name="Table Classic 3"/>

Name="Table Classic 4"/>

Name="Table Colorful 1"/>

Name="Table Colorful 2"/>

Name="Table Colorful 3"/>

Name="Table Columns 1"/>

Name="Table Columns 2"/>

Name="Table Columns 3"/>

Name="Table Columns 4"/>

Name="Table Columns 5"/>

Name="Table Grid 1"/>

Name="Table Grid 2"/>

Name="Table Grid 3"/>

Name="Table Grid 4"/>

Name="Table Grid 5"/>

Name="Table Grid 6"/>

Name="Table Grid 7"/>

Name="Table Grid 8"/>

Name="Table List 1"/>

Name="Table List 2"/>

Name="Table List 3"/>

Name="Table List 4"/>

Name="Table List 5"/>

Name="Table List 6"/>

Name="Table List 7"/>

Name="Table List 8"/>

Name="Table 3D effects 1"/>

Name="Table 3D effects 2"/>

Name="Table 3D effects 3"/>

Name="Table Contemporary"/>

Name="Table Elegant"/>

Name="Table Professional"/>

Name="Table Subtle 1"/>

Name="Table Subtle 2"/>

Name="Table Web 1"/>

Name="Table Web 2"/>

Name="Table Web 3"/>

Name="Balloon Text"/>

Name="Table Theme"/>

Name="List Paragraph"/>

Name="Intense Quote"/>

Name="Subtle Emphasis"/>

Name="Intense Emphasis"/>

Name="Subtle Reference"/>

Name="Intense Reference"/>

UnhideWhenUsed="true" Name="Bibliography"/>

UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>

Name="Grid Table 1 Light Accent 1"/>

Name="Grid Table 6 Colorful Accent 1"/>

Name="Grid Table 7 Colorful Accent 1"/>

Name="Grid Table 1 Light Accent 2"/>

Name="Grid Table 6 Colorful Accent 2"/>

Name="Grid Table 7 Colorful Accent 2"/>

Name="Grid Table 1 Light Accent 3"/>

Name="Grid Table 6 Colorful Accent 3"/>

Name="Grid Table 7 Colorful Accent 3"/>

Name="Grid Table 1 Light Accent 4"/>

Name="Grid Table 6 Colorful Accent 4"/>

Name="Grid Table 7 Colorful Accent 4"/>

Name="Grid Table 1 Light Accent 5"/>

Name="Grid Table 6 Colorful Accent 5"/>

Name="Grid Table 7 Colorful Accent 5"/>

Name="Grid Table 1 Light Accent 6"/>

Name="Grid Table 6 Colorful Accent 6"/>

Name="Grid Table 7 Colorful Accent 6"/>

Name="List Table 1 Light Accent 1"/>

Name="List Table 6 Colorful Accent 1"/>

Name="List Table 7 Colorful Accent 1"/>

Name="List Table 1 Light Accent 2"/>

Name="List Table 6 Colorful Accent 2"/>

Name="List Table 7 Colorful Accent 2"/>

Name="List Table 1 Light Accent 3"/>

Name="List Table 6 Colorful Accent 3"/>

Name="List Table 7 Colorful Accent 3"/>

Name="List Table 1 Light Accent 4"/>

Name="List Table 6 Colorful Accent 4"/>

Name="List Table 7 Colorful Accent 4"/>

Name="List Table 1 Light Accent 5"/>

Name="List Table 6 Colorful Accent 5"/>

Name="List Table 7 Colorful Accent 5"/>

Name="List Table 1 Light Accent 6"/>

Name="List Table 6 Colorful Accent 6"/>

Name="List Table 7 Colorful Accent 6"/>

/* Style Definitions */

table.MsoNormalTable

{mso-style-name:"Table Normal";

mso-tstyle-rowband-size:0;

mso-tstyle-colband-size:0;

mso-style-noshow:yes;

mso-style-priority:99;

mso-style-parent:"";

mso-padding-alt:0in 5.4pt 0in 5.4pt;

mso-para-margin:0in;

mso-para-margin-bottom:.0001pt;

mso-pagination:widow-orphan;

font-size:10.0pt;

font-family:"Times New Roman","serif";}

1.   Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44(7): 2064-89. Erratum in: Stroke 2019; 50(8): e239. [CrossRef] [PubMed]

2.   Marciniec M, Popek-Marciniec S, Kulczyński M, Pasterczyk K, Szczepańska-Szerej A, Rejdak K. Prevention of seizures after ischemic stroke: association between statin use and the risk  of seizures. World Sci News 2018; 99: 181-92. http://www.worldscientificnews.com/wp-content/uploads/2018/04/WSN-99-2018-181-192.pdf

3.   Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55(4): 475-82. [CrossRef] [PubMed]

4.   Merkler AE, Gialdini G, Lerario MP, Parikh NS, Morris NA, Kummer B, et al. Population-Based Assessment of the Long-Term Risk of Seizures in Survivors of Stroke. Stroke 2018; 49(6): 1319-24. [CrossRef] [PubMed]

5.   Van Tuijl JH, Van Raak EPM, Van Oostenbrugge RJ, Aldenkamp AP, Rouhl RPW. The occurrence of seizures after ischemic stroke does not influence long-term mortality; a 26-year follow-up study. J Neurol 2018; 265(8): 1780-8. [CrossRef] [PubMed]

6.   Ferro JM, Pinto F. Poststroke epilepsy: epidemiology, pathophysiology and management. Drugs Aging 2004; 21(10): 639-53. [CrossRef] [PubMed]

7.   Camilo O, Goldstein LB. Seizures and epilepsy after ischemic stroke. Stroke 2004; 35(7): 1769-75. [CrossRef] [PubMed]

8.   Yang H, Rajah G, Guo A, Wang Y, Wang Q. Pathogenesis of epileptic seizures and epilepsy after stroke. Neurol Res 2018; 40(6): 426-32. [CrossRef] [PubMed]

9.   Tanaka T, Ihara M. Post-stroke epilepsy. Neurochem Int 2017; 107: 219-28. [CrossRef] [PubMed]

10.       Lyden PD, Lu M, Levine SR, Brott TG, Broderick J. NINDS rtPA Stroke Study Group. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke 2001; 32(6): 1310-7. [CrossRef] [PubMed]

11.       Syvertsen M, Nakken KO, Edland A, Hansen G, Hellum MK, Koht J. Prevalence and etiology of epilepsy in a Norwegian county-A population based study. Epilepsia 2015; 56(5): 699-706. [CrossRef] [PubMed]

12.       Beleza P. Acute symptomatic seizures: a clinically oriented review. Neurologist 2012; 18(3): 109-19. [CrossRef] [PubMed]

13.       De Herdt V, Dumont F, Hénon H, Derambure P, Vonck K, Leys D, et al. Early seizures in intracerebral hemorrhage: incidence, associated factors, and outcome. Neurology 2011; 77(20): 1794-800. [CrossRef] [PubMed]

14.       Arntz RM, Maaijwee NA, Rutten-Jacobs LC, Schoonderwaldt HC, Dorresteijn LD, Van Dijk EJ, et al. Epilepsy after TIA or stroke in young patients impairs long-term functional outcome: the FUTURE Study. Neurology 2013; 81(22): 1907-13. [CrossRef] [PubMed]

15.       Arntz R, Rutten-Jacobs L, Maaijwee N, Schoonderwaldt H, Dorresteijn L, Van Dijk E, et al. Post-stroke epilepsy in young adults: a long-term follow-up study. PLoS One 2013; 8(2): e55498. [CrossRef] [PubMed]

16.       Arntz RM, Rutten-Jacobs LC, Maaijwee NA, Schoonderwaldt HC, Dorresteijn LD, van Dijk EJ, et al. Poststroke epilepsy is associated with a high mortality after a stroke at young age: follow-up of transient ischemic attack and stroke patients and unelucidated risk factor evaluation study. Stroke 2015; 46(8): 2309-11. [CrossRef] [PubMed]

17.       Conrad J, Pawlowski M, Dogan M, Kovac S, Ritter MA, Evers S. Seizures after cerebrovascular events: risk factors and clinical features. Seizure 2013; 22(4): 275-82. [CrossRef] [PubMed]

18.       Misirli H, Ozge A, Somay G, Erdoğan N, Erkal H, Erenoğlu NY. Seizure development after stroke. Int J Clin Pract 2006; 60(12): 1536-41. [CrossRef] [PubMed]

19.       Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ 1997; 315(7122): 1582-7. [CrossRef] [PubMed]

20.       Sarecka-Hujar B, Kopyta I. Poststroke epilepsy: current perspectives on diagnosis and treatment. Neuropsychiatr Dis Treat 2018; 15: 95-103. [CrossRef] [PubMed]

21.       Graham NS, Crichton S, Koutroumanidis M, Wolfe CD, Rudd AG. Incidence and associations of poststroke epilepsy: the prospective South London Stroke Register. Stroke 2013; 44(3): 605-11. [CrossRef] [PubMed]

22.       Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, Coté R, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol 2000; 57(11): 1617-22. [CrossRef] [PubMed]

23.       Chiu D, Peterson L, Elkind MSV, Rosand J, Gerber LM, Silverstein MD; Glycine Antagonist in Neuroprotection (GAIN) Americas Trial Investigators. Comparison of outcomes after intracerebral hemorrhage and ischemic stroke. J Stroke Cerebrovasc Dis. 2010; 19(3): 225-9. [CrossRef] [PubMed]

24.       Di Maio R. Neuronal mechanisms of epileptogenesis. Front Cell Neurosci 2014; 8: 29. [CrossRef] [PubMed]

25.       Zelano J. Poststroke epilepsy: update and future directions. Ther Adv Neurol Disord 2016; 9(5): 424-35. [CrossRef] [PubMed]

26.       Beghi E, D'Alessandro R, Beretta S, Consoli D, Crespi V, Delaj L, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology 2011; 77(20): 1785-93. [CrossRef] [PubMed]

27.       Lamy C, Domigo V, Semah F, Arquizan C, Trystram D, Coste J, et al. Early and late seizures after cryptogenic ischemic stroke in young adults. Neurology 2003; 60(3): 400-4. [CrossRef] [PubMed]

28.       Reith J, Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS. Seizures in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke 1997; 28(8): 1585-9. [CrossRef] [PubMed]

29.       Jungehulsing GJ, Heuschmann PU, Holtkamp M, Schwab S, Kolominsky-Rabas PL. Incidence and predictors of post-stroke epilepsy. Acta Neurol Scand 2013; 127(6): 427-30. [CrossRef] [PubMed]

30.       Boison D, Sandau US, Ruskin DN, Kawamura M Jr, Masino SA. Homeostatic control of brain function - new approaches to understand epileptogenesis. Front Cell Neurosci 2013; 7: 109. [CrossRef] [PubMed]

31.       Henshall DC, Engel T. Contribution of apoptosis-associated signaling pathways to epileptogenesis: lessons from Bcl-2 family knockouts. Front Cell Neurosci 2013; 7: 110. [CrossRef] [PubMed]

32.       Hamer HM. Epileptische Anfälle und Epilepsien nach "Schlaganfall" [Seizures and epilepsies after stroke]. Nervenarzt 2009; 80(4): 405-14. [CrossRef] [PubMed]

33.       Gilad R, Sadeh M, Rapoport A, Dabby R, Boaz M, Lampl Y. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007; 30(4):189-95. [CrossRef] [PubMed]

34.       Sykes L, Wood E, Kwan J. Antiepileptic drugs for the primary and secondary prevention of seizures after stroke. Cochrane Database Syst Rev 2014; (1): CD005398. [CrossRef] [PubMed]

35.       Qian C, Löppönen P, Tetri S, Huhtakangas J, Juvela S, Turtiainen HM, et al. Immediate, early and late seizures after primary intracerebral hemorrhage. Epilepsy Res 2014; 108(4): 732-9. [CrossRef] [PubMed]

Objavljeno
2023/04/11
Rubrika
Originalni rad